"Esophagogastric Junction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice.
| Descriptor ID |
D004943
|
| MeSH Number(s) |
A03.556.875.500.414 A03.556.875.875.330
|
| Concept/Terms |
Esophagogastric Junction- Esophagogastric Junction
- Junction, Esophagogastric
- Gastroesophageal Junction
- Gastroesophageal Junctions
- Junction, Gastroesophageal
- Junctions, Gastroesophageal
|
Below are MeSH descriptors whose meaning is more general than "Esophagogastric Junction".
Below are MeSH descriptors whose meaning is more specific than "Esophagogastric Junction".
This graph shows the total number of publications written about "Esophagogastric Junction" by people in this website by year, and whether "Esophagogastric Junction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 5 | 0 | 5 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 5 | 2 | 7 |
| 2005 | 1 | 2 | 3 |
| 2006 | 6 | 3 | 9 |
| 2007 | 7 | 1 | 8 |
| 2008 | 5 | 2 | 7 |
| 2009 | 3 | 1 | 4 |
| 2010 | 4 | 1 | 5 |
| 2011 | 4 | 0 | 4 |
| 2012 | 6 | 3 | 9 |
| 2013 | 5 | 0 | 5 |
| 2014 | 4 | 3 | 7 |
| 2015 | 7 | 3 | 10 |
| 2016 | 11 | 7 | 18 |
| 2017 | 9 | 3 | 12 |
| 2018 | 5 | 0 | 5 |
| 2019 | 6 | 2 | 8 |
| 2020 | 3 | 1 | 4 |
| 2021 | 6 | 5 | 11 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 15 | 15 |
| 2024 | 8 | 4 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Esophagogastric Junction" by people in Profiles.
-
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. JCO Precis Oncol. 2024 Dec; 8:e2400288.
-
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024 Sep 26; 391(12):1159-1162.
-
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024 Aug; 9(8):103663.
-
Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers. Br J Cancer. 2024 Sep; 131(5):797-807.
-
Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience. Int J Cancer. 2024 Dec 15; 155(12):2277-2286.
-
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024 Sep; 27(5):1058-1068.
-
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncol. 2024; 20(26):1861-1877.
-
Palliative Surgery for Patients with Gastroesophageal Junction or Gastric Cancer: A Report on Clinical Observational Outcomes. Ann Surg Oncol. 2024 Aug; 31(8):5252-5262.
-
Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma. JCO Precis Oncol. 2024 May; 8:e2300543.
-
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024 Apr; 30(4):1023-1034.